Personalized, Precise, Measurable

Plaque, stenosis, and ischemia — all in one AI-enabled CCTA solution

Learn how Cleerly works

Today’s symptom-focused approach to cardiovascular care is flawed – but we have the tools to change it.
James Min, MD
Founder and CEO of Cleerly

How Cleerly Transforms Cardiac Risk Assessment

Cleerly’s AI algorithms rapidly interpret coronary computed tomography angiography (CCTA) scans to generate a 3D model of the coronary arteries, locate and quantify stenoses, as well as identify, quantify and categorize types of plaque.

When CCTA with Cleerly is included as an element of a physician’s workflow, it can be a powerful diagnostic aid that can reveal the degree of atherosclerosis, stenosis, and likelihood of ischemia, as well as provide clear measurements of changes in disease.

 

Cleerly is Diagnostically Accurate

Multicenter and single-center clinical trials have consistently demonstrated Cleerly’s robust clinical utility, including higher diagnostic accuracy, over tests such as nuclear SPECT stress testing.1-7

In a post-hoc analysis of the independent PACIFIC study, Cleerly ISCHEMIA demonstrated higher diagnostic accuracy compared with SPECT and similar accuracy to PET in the prediction of ischemia.1

Compared to CCTA alone, Cleerly reduces the overestimation of stenosis seen commonly with clinical readers.7-8

Cleerly is diagnostically accurate
 

Cleerly Informs Action

In the CERTAIN trial, compared to conventional CCTA interpretation alone, the use of Cleerly’s products led to significant changes in clinical decision-making and patient management in more than 57% of patients, and increased physicians’ diagnostic confidence five-fold compared to a standard assessment of CCTA.9

Use of Cleerly also resulted in a 39% change in the degree of coronary stenosis, a 37% reduction in the need for further invasive and non-invasive testing, and a 28% increase in the use of preventive medications.9

cleerly-informs-action
 

Cleerly is Confirmed

In 2021, the American College of Cardiology (ACC), American Heart Association (AHA), and other groups, identified CCTA as a Class 1 recommendation, with level A of evidence, in the evaluation of patients with stable and acute chest pain who have no known coronary artery disease (CAD).10

Cleerly analyses are clinically validated,1-9 and can be billed using CPT® Code 75580 for Cleerly ISCHEMIA, as well as codes 0623T, 0624T, 0625T, 0626T for reporting Cleerly’s advanced coronary atherosclerosis analysis.

Cleerly confirmed as CCTA Class 1A recommendation
Cleerly ISCHEMIA Clinical Evidence
Request a Demo

Interested in integrating Cleerly ISCHEMIA and plaque analyses into your practice?
Request a time for your personalized demo of the software and learn how we can complement your care approach.

Request demo ⏵

 

Download

Cleerly ISCHEMIA Clinical Evidence
 
Download Now
Heart disease is still the leading cause of death in the United States. We've obviously been missing something. If we can see it early and affect change, then it will save lives. That's why Cleerly is a game changer.
Dr. Michale Barber, MD
CEO and CMO, Better Life Carolinas
 
Cleerly FAQs
 

Request a Demo

Interested in integrating Cleerly ISCHEMIA and plaque analyses into your practice? Request a time for your personalized demo of the software and learn how we can complement your care approach.